UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2022

Commission File Number: 001-40488

Molecular Partners AG
(Translation of registrant's name into English)

Wagistrasse 14
8952 Zurich-Schlieren
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):        

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):        

EXHIBIT INDEX

Exhibit No.   Description
     
99.1   American Society for Microbiology: ASM MICROBE - poster presentation; Title: SARS-CoV-2 Omicron And Multi-variant Neutralization Activity Of Ensovibep: A DARPin Therapeutic Candidate For Treatment Of Covid-19 (a Novartis poster presentation)    

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

        Molecular Partners AG    
    (Registrant)
     
   
Date: June 13, 2022       /s/ PATRICK AMSTUTZ    
    Patrick Amstutz
    Chief Executive Officer
   
Molecular Partners (CE) (USOTC:MLLCF)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Molecular Partners (CE).
Molecular Partners (CE) (USOTC:MLLCF)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Molecular Partners (CE).